Retatrutide Research Peptide: What It Is, How It Works & What the Research Shows
If you’ve been hearing about retatrutide, you’ve probably noticed that it’s being discussed as a new kind of weight management medication. But what exactly is retatrutide, how does it work, and what does the research actually tell us?
Retatrutide, also known as LY3437943 or LY-3437943, is an investigational peptide being studied for its ability to activate three metabolic hormone receptors at once.
Early clinical research has produced significant interest, particularly around body weight, blood sugar, and other metabolic measures.
Here’s what we know so far and just as importantly, what researchers are still trying to understand:
- What is Retatrutide?
- What is Retatrutide Being Studied For?
- How Does Retatrutide Work?
- What Are the Potential Benefits of Retatrutide?
- What Are the Side Effects of Retatrutide?
- Retatrutide vs. Other Weight Loss Peptides
- Is Retatrutide FDA Approved?
- Why Does Research Grade Testing Matter
- Retatrutide Research Peptide Quality & COA
This article reviews the current scientific understanding of retatrutide, including its proposed mechanism of action, preclinical research, clinical evidence, research limitations, and regulatory status.
Research Use Only: Retatrutide is investigational and is not an FDA-approved medicine. Vital Tides Retatrutide is offered as lyophilized research material for controlled laboratory and analytical research only. It is not intended for human or veterinary use.
What Is Retatrutide?
Retatrutide, also known as LY3437943, is an investigational synthetic peptide being studied for its effects on several metabolic pathways. What makes retatrutide different from many other peptides currently being researched is that it is designed to activate three hormone receptors at the same time: GIP, GLP-1, and glucagon receptors.
In simple terms, researchers are studying whether activating these three pathways together can produce different metabolic effects than targeting one pathway or two pathways alone.
Retatrutide is sometimes referred to as a triple agonist because of this three receptor activity:
- GIP receptor (GIPR)
- GLP-1 receptor (GLP-1R)
- Glucagon receptor (GCGR)
These receptors are involved in processes such as glucose regulation, insulin signaling, appetite and energy balance, and the way the body handles energy and stored fat. This is the primary reason it has attracted significant interest in metabolic research.
Why Is Retatrutide Getting So Much Attention?
The interest in retatrutide isn’t based on its mechanism alone. Researchers have now studied the compound in multiple clinical trials, including research involving obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD) (MASLD).
In a 2023 Phase 2 obesity trial, researchers reported dose-dependent reductions in body weight over 48 weeks, with the highest-dose group experiencing a mean reduction of approximately 24% from baseline.
Retatrutide has also been studied in people with type 2 diabetes. A Phase 2 trial published in The Lancet found improvements in both blood glucose measures and body weight compared with placebo, while later research has continued evaluating the compound in larger Phase 3 trials.
Read more about these trials below in the section “What is Retatrutide Being Studied For?”
Is Retatrutide a GLP-1?
Not exactly.
Retatrutide activates the GLP-1 receptor, but it is not a GLP-1-only compound. Its distinguishing feature is that it activates GIP, GLP-1, and glucagon receptors together.
That distinction becomes important when comparing retatrutide with other metabolic peptides and medications because the three-receptor approach is what researchers are trying to understand.
Is Retatrutide a Medication?
Retatrutide is an investigational compound, meaning it is still being evaluated through clinical research. It is not FDA-approved for the treatment of obesity, diabetes, or another medical condition.
Vital Tides offers retatrutide as lyophilized research material for controlled laboratory and analytical research only. It is not intended for human or veterinary use.
Retatrutide Research Peptide at a Glance
| Attribute | Information |
|---|---|
| Compound | Retatrutide |
| Research identifier | LY3437943 / LY-3437943 |
| CAS number | 2381089-83-2 |
| Compound type | Synthetic triple-receptor agonist peptide |
| Research targets | GIPR, GLP-1R, and GCGR |
| Product form | Lyophilized research material |
| Available sizes | 5 mg, 10 mg, and 20 mg |
| Regulatory status | Investigational; not FDA-approved |
| Intended use | Controlled laboratory and analytical research only |
The short version: Retatrutide is an investigational peptide designed to activate three metabolic hormone receptors: GIP, GLP-1, and glucagon. Researchers are studying how this combination affects body weight, blood sugar, energy balance, and other metabolic pathways. Early and later-stage clinical research has produced significant interest, but retatrutide remains investigational and is not an FDA-approved medication.
What Is Retatrutide Being Studied For?
Retatrutide is being studied primarily for its potential effects on body weight, blood sugar, and other aspects of metabolic health. Researchers are also investigating how its three-receptor activity may affect energy balance, body composition, and liver fat.
Because retatrutide is still investigational, these are areas of research, not approved medical uses.
Researchers interested in laboratory applications can learn more about our Retatrutide research peptide.
Weight and Obesity Research
Weight management has been one of the biggest areas of interest in retatrutide research. In a 2023 Phase 2 clinical trial involving adults with obesity, researchers found that retatrutide produced dose-dependent reductions in body weight over 48 weeks. The highest-dose group had an average weight reduction of 24.2% from baseline.
Those results are one reason retatrutide has received so much attention. However, a clinical trial result describes what happened within that study population; it does not mean every person would experience the same result.
Blood Sugar and Metabolic Research
Researchers are also studying retatrutide in people with type 2 diabetes. In a Phase 2 trial published in The Lancet, retatrutide was evaluated against placebo and dulaglutide. The study found improvements in measures of blood sugar control as well as reductions in body weight.
This research is helping scientists understand how activating GIP, GLP-1, and glucagon receptors together may influence glucose regulation and other metabolic processes.
Energy Balance and Body Composition
Another area of interest is how the body uses and stores energy.
Researchers are studying retatrutide in relation to food intake, energy expenditure, body composition, and metabolic signaling. The glucagon component of retatrutide’s activity is particularly interesting because glucagon signaling is involved in energy metabolism and substrate use.
Researchers have also examined changes in body composition during retatrutide treatment, helping to look beyond the number on the scale and understand how changes in body weight may relate to fat mass and lean mass.
Liver and Metabolic Research
Retatrutide has also been studied in people with metabolic dysfunction-associated steatotic liver disease (MASLD).
In a Phase 2a study, researchers investigated retatrutide’s effects on liver fat and other measures associated with metabolic liver disease. This research adds another area of interest to the broader study of retatrutide and metabolic health.
Why Are Researchers Studying So Many Different Areas?
The answer comes back to retatrutide’s three-receptor activity.
Rather than targeting only one metabolic pathway, retatrutide is designed to activate GIP, GLP-1, and glucagon receptors simultaneously. Researchers are therefore interested in how those signals work together and whether the combination produces effects that are different from single- or dual-receptor approaches.
Research note: The areas discussed above describe ongoing and completed clinical research. They should not be interpreted as approved uses, medical recommendations, or evidence that research-grade retatrutide is safe or effective for human use.
How Does Retatrutide Work?
Retatrutide is designed to activate three hormone receptors: GIP, GLP-1, and glucagon. Because it targets all three pathways in one molecule, researchers describe it as a triple-receptor agonist.
Each pathway plays a different role in metabolism:
- GLP-1: Involved in blood sugar regulation, insulin signaling, appetite, and digestion.
- GIP: Involved in nutrient and glucose signaling, including insulin secretion.
- Glucagon: Plays a role in blood glucose regulation and energy metabolism.
Why Combine All Three?
The idea behind retatrutide is that these pathways may work together rather than independently. GLP-1 and GIP signaling can influence appetite, insulin, and glucose regulation, while glucagon signaling is being studied for its potential effects on energy expenditure and the way the body uses stored energy.
Researchers are interested in whether activating all three receptors can produce different metabolic effects than activating only one or two. This is one of the main reasons retatrutide is being studied alongside other single- and dual-receptor approaches.
What Are the Potential Benefits of Retatrutide?
Retatrutide is still investigational, but clinical research has produced promising findings across several areas of metabolic health, including body weight, blood sugar, body composition, and liver fat.
Weight Management
Weight reduction is one of the primary areas being investigated. Clinical trials have found significant, dose-dependent reductions in body weight, while researchers are also examining the role of appetite and energy balance in these results.
Blood Sugar and Metabolic Health
Studies in people with type 2 diabetes have found improvements in measures of blood sugar control, along with reductions in body weight. Researchers are continuing to examine how retatrutide’s combined GIP, GLP-1, and glucagon activity influences glucose and insulin signaling.
Body Composition
The research also goes beyond overall weight. Studies have reported reductions in waist circumference and abdominal fat, including both visceral and subcutaneous fat.
Liver Fat
Retatrutide has also been investigated in people with metabolic dysfunction-associated steatotic liver disease (MASLD). In a Phase 2a study, the 12-mg group experienced an 82.4% relative reduction in liver fat at 24 weeks compared with baseline.
Retatrutide Before and After: What Do Clinical Trials Actually Show?
Rather than relying on individual before-and-after photos, clinical trial data gives us a more reliable way to understand the changes observed with retatrutide.
In the 48-week Phase 2 obesity trial, participants receiving the highest dose had an average 24.2% reduction in body weight.
The study also found that 83% of participants in the 12-mg group lost at least 15% of their starting body weight, while 26% lost at least 30%. Waist circumference decreased by as much as 19.6 cm across the retatrutide groups.
These figures represent results from a specific clinical trial and should not be interpreted as a prediction for an individual. Outcomes can vary based on factors such as dose, study population, and individual response.
The research is encouraging, but these remain clinical research findings—not guaranteed results or approved medical benefits.
What Are the Side Effects of Retatrutide?
The side effects reported in retatrutide clinical research have been primarily gastrointestinal, including nausea, diarrhea, vomiting, and constipation. In the Phase 2 obesity trial, these effects were generally mild to moderate, occurred most often during dose increases, and were more common at higher doses.
Researchers also observed dose-dependent increases in heart rate, which peaked around 24 weeks and declined afterward. The trial also reported some changes in pancreatic enzymes and isolated cases of other adverse events, including one case of acute pancreatitis.
This is important context when reading about retatrutide: clinical trials are designed to identify both potential benefits and potential risks. A side effect occurring during a trial does not necessarily mean the compound caused it, which is why researchers compare events between treatment and placebo groups and continue monitoring participants in larger studies.
What About Long-Term Effects?
This is one of the questions researchers are still working to answer. Retatrutide has been studied for periods of up to 48 weeks in the early published obesity research, while ongoing clinical development is evaluating longer-term safety and outcomes.
That means we do not yet have a complete picture of the long-term effects of retatrutide. Questions about prolonged use, long-term cardiovascular outcomes, durability of effects, and other potential risks require longer follow-up and additional research.
For that reason, retatrutide should be viewed as an investigational compound, not as a proven long-term treatment.
Retatrutide vs. Other Weight Loss Peptides
Retatrutide is different from many other weight-management peptides because it targets three hormone receptors, GIP, GLP-1, and glucagon, instead of one or two. This is why researchers describe it as a triple agonist.
For comparison, GLP-1 receptor agonists primarily target the GLP-1 pathway, while dual GIP/GLP-1 agonists target two pathways. Retatrutide adds glucagon receptor activity to the GIP and GLP-1 pathways.
That doesn’t automatically mean retatrutide is better than other peptides. It means researchers are investigating a different approach to metabolic signaling, including whether activating three pathways can produce different effects on body weight, blood sugar, and energy metabolism.
Is Retatrutide FDA Approved?
No. Retatrutide is not FDA-approved. It remains an investigational medication being studied in clinical trials.
The FDA explains that investigational drugs are compounds still being studied to determine whether they are safe and effective and how they may ultimately be used.
This distinction matters: promising clinical-trial results do not mean a compound has received regulatory approval.
Vital Tides retatrutide is offered as research material for controlled laboratory and analytical research only and is not intended for human or veterinary use.
Why Does Research Grade Testing Matter?
When you’re working with research material, knowing exactly what you’re working with matters. Research-grade testing can provide information about a material’s identity, purity, assay, and other quality characteristics for the specific lot tested.
A Certificate of Analysis (COA) documents the results of testing performed on a particular sample or lot. It gives researchers a way to review supporting analytical information instead of relying solely on a product label.
However, a COA is not the same thing as FDA approval, and a laboratory test result does not establish that a research peptide is safe or effective for human use.
For researchers, the goal is simple: know what the material is, know what testing was performed, and have documentation you can verify.
Retatrutide Research Peptide Quality & COA
For research materials, analytical documentation can help researchers review the characteristics of a specific lot. A Certificate of Analysis may include information such as identity, purity, assay, and other quality measurements depending on the testing performed.
Researchers should review the available analytical documentation for the specific material and lot they are evaluating.
Frequently Asked Questions About Retatrutide
What is retatrutide peptide?
Retatrutide, also known as LY3437943, is an investigational peptide designed to activate three receptors: GIP, GLP-1, and glucagon. This makes it a triple-receptor agonist.
What is retatrutide being studied for?
Researchers are studying retatrutide primarily in areas including obesity, type 2 diabetes, metabolic health, and liver fat. Current clinical development is also investigating additional conditions and outcomes.
Is retatrutide a GLP-1?
Retatrutide activates the GLP-1 receptor, but it is not a GLP-1-only compound. It also activates GIP and glucagon receptors, which is why it is classified as a triple agonist.
What makes retatrutide different from other weight-loss peptides?
The main difference is its three-receptor activity. Retatrutide targets GIP, GLP-1, and glucagon, while other compounds may target one or two of these pathways. Researchers are studying whether this broader activity produces different metabolic effects.
How much weight loss has been observed with retatrutide?
In a 48-week Phase 2 obesity trial, participants receiving the highest studied dose had an average 24.2% reduction in body weight. Individual results varied, and these findings should not be interpreted as a prediction of what any individual will experience.
What side effects have been reported with retatrutide?
The most frequently reported side effects in the Phase 2 obesity trial were nausea, diarrhea, vomiting, and constipation. These gastrointestinal effects occurred most often during dose increases and were generally mild to moderate.
Is retatrutide FDA approved?
No. Retatrutide is still investigational and has not been approved by the FDA. The FDA has specifically stated that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
Is retatrutide available to the public?
Retatrutide is not currently approved for general public use. It remains under clinical investigation, with Phase 3 studies ongoing.
What is a retatrutide COA?
A Certificate of Analysis (COA) is documentation showing the results of analytical testing performed on a particular sample or lot. Depending on the testing performed, it may provide information such as identity, purity, assay, and other quality measurements.
For research materials, a COA can help researchers verify the analytical information associated with the specific material they received. It does not establish FDA approval or prove that a product is safe for human use.
Is retatrutide the same as “GLP-3”?
No. “GLP-3” is an informal term, not a recognized scientific classification. Retatrutide is more accurately described as a triple agonist because it activates the GIP, GLP-1, and glucagon receptors.
How long have researchers been studying retatrutide?
Retatrutide has progressed from early clinical research into Phase 3 clinical trials, with ongoing studies evaluating its safety and effectiveness across several conditions. Because development is still ongoing, researchers are continuing to collect longer-term safety and efficacy data.
Research & References
- Jastreboff, A. M., et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” The New England Journal of Medicine, 2023.
View the clinical trial - Rosenstock, J., et al. “Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, in People with Type 2 Diabetes.” The Lancet, 2023.
View the clinical trial - Sanyal, A. J., et al. “Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial.” Nature Medicine, 2024.
View the study - Eli Lilly and Company. “What to Know About Retatrutide.”
View Eli Lilly’s retatrutide information - U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.”
View the FDA guidance
Continue Your Research
Retatrutide represents one example of a broader area of research into multi-receptor metabolic signaling.
Researchers interested in incretin biology, glucagon signaling, metabolic pathways, and peptide pharmacology can explore related research literature and compounds through the Vital Tides research catalog.
Explore the Vital Tides Research Catalog →
Research Use Disclaimer
The information presented in this article is provided for educational and scientific research purposes only. Retatrutide is an investigational compound and has not been approved by the U.S. Food and Drug Administration (FDA). Information regarding mechanisms, research applications, and clinical findings reflects available scientific literature and should not be interpreted as medical advice, treatment recommendations, or evidence of safety or efficacy for human or veterinary use.
Vital Tides Retatrutide is offered as research material for controlled laboratory and analytical research only. Product information, analytical results, and research literature should be evaluated independently by qualified researchers within the appropriate regulatory and laboratory framework.
This article does not constitute a recommendation for human or veterinary administration.